Cinclus Pharma (Q3 review): Pivotal studies underway - Redeye

Redeye provides a research update following the Q3 report published by Cinclus earlier today. The financials in the report did not contain any major surprises. Instead, the headline for the quarter is the initiation of the company’s pivotal phase III study. With recruitment in full swing, we await topline results anticipated in H2 2026e.

Länk till analysen i sin helhet: https://www.redeye.se/research/1140120/cinclus-pharma-q3-review-pivotal-studies-underway?utm_source=finwire&utm_medium=RSS